Infection in ICU
6
2
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Early Optimization of Ceftazidime Regimen in Critical Care
Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis
Measurement of Intestinal Permeability in Intensive Care Patients With Single or Multiple Organ Failure
Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline
The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?
Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients